An Open-Label Pilot Study of Sublocade as Treatment for Opiate Use Disorder

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

March 1, 2019

Primary Completion Date

February 28, 2020

Study Completion Date

February 28, 2020

Conditions
Opioid-use Disorder
Interventions
DRUG

Sublocade

The monthly Sublocade buprenorphine extended-release (BXR) injection will be administered in two doses (100 mg and 300 mg). Following a 4 day induction onto oral buprenorphine, the first 300 mg injection of Sublocade will be administered. A second 300 mg Sublocade injection will be administered 1 month later and the third and final monthly injection of 100 mg of Sublocade will be administered 2 months post the successful buprenorphine induction.

Trial Locations (1)

10019

Substance Treatment Research Service (STARS) of Columbia University, New York

All Listed Sponsors
lead

New York State Psychiatric Institute

OTHER